Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
Désirée Mfm van der HeijdeAtul DeodharWalter P MaksymowychJoachim SieperFilip Van den BoschTae Hwan KimKishimoto MitsumasaAndrew J K OstorBernard CombeYunxia SuiYuanyuan DuanPeter K WungIn-Ho SongPublished in: RMD open (2022)
Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 2 years for ASAS40 and other clinically relevant endpoints. A low rate of radiographic progression was observed and no new safety findings were observed.